Nguyen Tuyet A, DeShazo Jonathan P, Thacker Leroy R, Puri Puneet, Sanyal Arun J
Division of Gastroenterology and Hepatology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Department of Health Administration, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Alcohol Clin Exp Res. 2016 Jun;40(6):1295-303. doi: 10.1111/acer.13069. Epub 2016 May 5.
Alcoholic hepatitis (AH) is a major cause of liver-related hospitalization. The profile, treatment patterns, and outcomes of subjects admitted for AH in routine clinical practice are unknown. Also, it is not known whether these are changing over time. This study is thus aimed to identify temporal trends in hospitalization rates, clinical characteristics, treatment patterns, and outcomes of subjects admitted for AH in a routine clinical setting.
A retrospective analysis of adults admitted for AH from 2000 to 2011 was performed using an anonymized EMR database of patient-level data from 169 U.S. medical centers.
(i)
The proportion of baby boomers admitted for AH increased from 2000 to 2011 (26 to 31%, p < 0.0001). (ii)
The median Model for End-Stage Liver Disease (MELD) score increased over time from 12 to 14 (p = 0.0014) driven mainly by increased international normalized ratio (1.2 to 1.4, p < 0.0001). The median Charlson Comorbidity Index increased from 0 to 1 (p < 0.0001) with increased diabetes, chronic obstructive pulmonary disease, and heart disease. (iii)
The following increased from 2001 to 2011: Gastrointestinal bleed-7 to 10% (p = 0.03); hepatic encephalopathy-7 to 13% (p < 0.0001); hepatorenal syndrome-1.8 to 2.8% (p = 0.0003); sepsis-0 to 6% (p < 0.0001); and pancreatitis-11 to 16% (p = 0.0061). (iv) Treatment patterns and mortality: Eight to 9% of subjects received steroids while pentoxifylline use increased to 2.2%. In those with MELD ≥ 22, mortality remained between 19 and 20% and only steroids modestly improved survival in this subset.
Severe AH continues to have a high mortality. The severity and comorbidities and complications associated with AH have worsened. Drug therapy remains suboptimal.
酒精性肝炎(AH)是肝脏相关住院治疗的主要原因。在常规临床实践中,因AH入院患者的概况、治疗模式及预后尚不清楚。此外,也不清楚这些情况是否随时间而变化。因此,本研究旨在确定在常规临床环境中,因AH入院患者的住院率、临床特征、治疗模式及预后的时间趋势。
利用来自169家美国医疗中心的患者层面数据的匿名电子病历数据库,对2000年至2011年因AH入院的成年人进行回顾性分析。
(i)
2000年至2011年,因AH入院的婴儿潮一代比例有所增加(从26%增至31%,p<0.0001)。(ii)
终末期肝病模型(MELD)评分中位数随时间从12增至14(p=0.0014),主要是由于国际标准化比值升高(从1.2增至1.4,p<0.0001)。查尔森合并症指数中位数从0增至1(p<0.0001),糖尿病、慢性阻塞性肺疾病和心脏病患者增多。(iii)
2001年至2011年,以下并发症有所增加:胃肠道出血从7%增至10%(p=0.03);肝性脑病从7%增至13%(p<0.0001);肝肾综合征从1.8%增至2.8%(p=0.0003);脓毒症从0增至6%(p<0.0001);胰腺炎从11%增至16%(p=0.0061)。(iv)治疗模式与死亡率:8%至9%的患者接受了类固醇治疗,而己酮可可碱的使用增加至2.2%。在MELD≥22的患者中,死亡率维持在19%至20%之间,只有类固醇能适度改善该亚组患者的生存率。
重度AH的死亡率仍然很高。与AH相关的严重程度、合并症及并发症有所恶化。药物治疗仍不理想。